The Medicines Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From The Medicines Company
The company will determine whether a single administration of autologous regulatory T-cells (Tregs) can reset and restore immune tolerance in autoimmune, inflammatory and neuroinflammatory diseases.
Mergers and acquisitions are set to gain momentum in South Korea as firms outside the sector seek new growth engines and more open-minded biopharma companies seek rapid growth and globalization.
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
BTK Inhibitors could be a major advance multiple sclerosis therapy, and Biogen has bought into a potential challenger to Phase III frontrunner from Sanofi and Roche.
- Other Names / Subsidiaries
- Annovation Biopharma, Inc.
- Boxford Subsidiary
- Curacyte Discovery GmbH
- Incline Therapeutics, Inc.
- ProFibrix B.V.
- Rempex Pharmaceuticals, Inc.
- Targanta Therapeutics Corporation
- Tenaxis Medical